

## CALL TEXT

Sixth transnational call for research projects for the JPIAMR within the **ERA-NET JPI-EC-AMR**

---

### **“Innovations against antibiotic-resistant bacteria: new targets, compounds and tools Fundamental, translational research, with the exception of clinical trials.”**

#### **1. Aim of the call**

The primary aim of the sixth joint call of the Joint Programming Initiative on Antimicrobial Resistance (JPIAMR) is to combine the resources, infrastructures, and research strengths of multiple countries in order to address **the identification and validation of new targets, the development of new therapies, and new tools for new treatments** (including new antibiotics).

The goal is to foster multinational research collaborations to add value to, and to build upon, the research conducted independently at national level, as well as to work together to develop new and urgently needed therapies.

A number of bacterial pathogens are associated with an alarming increase in rates of drug resistance development in healthcare and community settings. In September 2017, WHO published the Global priority list of antibiotic-resistant bacteria<sup>1</sup> with the aim to guide research, and the discovery and development of new therapies. The priority pathogens list have been classified according to three categories:

- Priority 1 : Critical
  - *Acinetobacter baumannii*; carbapenem-resistant
  - *Pseudomonas aeruginosa*; carbapenem-resistant
  - *Enterobacteriaceae* (*Klebsiella pneumoniae*, *Escherichia coli*, *Enterobacter* spp., *Serratia* spp., *Proteus* spp., *Providencia* spp. and *Morganella* spp.); carbapenem-resistant, 3<sup>rd</sup> generation cephalosporin-resistant
- Priority 2 : High
  - *Enterococcus faecium* ; vancomycin-resistant
  - *Staphylococcus aureus*; methicillin-resistant, vancomycin intermediate and resistant
  - *Helicobacter pylori*; clarithromycin-resistant
  - *Campylobacter*; fluoroquinolone-resistant
  - *Salmonella* spp.; fluoroquinolone-resistant
  - *Neisseria gonorrhoeae*; 3<sup>rd</sup> generation cephalosporin-resistant, fluoroquinolone-resistant
- Priority 3: Medium
  - *Streptococcus pneumoniae*; penicillin-non-susceptible
  - *Haemophilus influenzae*; ampicillin-resistant
  - *Shigella* spp.; fluoroquinolone-resistant

In addition of those three priority classes, *Mycobacterium tuberculosis* multi- and extensively drug resistant has also been identified as a priority for discovery and the development of new therapies.

---

<sup>1</sup>[http://www.who.int/medicines/areas/rational\\_use/PPLreport\\_2017\\_09\\_19.pdf?ua=1](http://www.who.int/medicines/areas/rational_use/PPLreport_2017_09_19.pdf?ua=1)

JPIAMR has the objective to address the major societal challenge of AMR, which no country is capable of handling on its own. This includes alignment of national, European and international policies, programs and issuing calls, a large spectrum of joint activities in the field of AMR, as well as updating the JPIAMR strategic research agenda (SRA). The JPIAMR thus promotes transnational cooperation in order to combine resources, infrastructures and research strengths to overcome the challenge of antimicrobial resistance.

Control of AMR needs actions addressing issues at human, animal and environmental levels, according to an approach usually referred to as “One Health”. Following publication of the WHO Global priority list of antibiotic-resistant bacteria (including *Mycobacterium tuberculosis* multi- and extensively drug resistant), the JPIAMR is launching a joint transnational call with the aim to discover new targets, compounds and tools with the potential to help controlling diseases caused by resistant bacteria from the above-mentioned WHO pathogen list in human, animal or environmental settings.

Projects considered for funding will involve fundamental and/or translational research, with the exception of clinical trials.

### 1.1 Topics of the call

The call will cover research tackling the bacterial pathogens and the resistances identified by the WHO (see list above). For the JPI AMR, research on the bacterial pathogens of priority 1, 2 or 3 are equal in relevance for this call.

The proposal should address at least one of the following topics:

- New targets:
  - Studies of new bacterial targets or mechanisms of resistance (examples include studies on novel enzyme or efflux pump inhibitors or others), including studies aimed at understanding and overcoming the mechanisms controlling the generation of resistance.
- New therapies:
  - Discovery of new compounds (including new antibiotics and alternatives).
  - Strategies to inhibit or reduce the acquisition of resistance, such as single molecular agents effective against multiple targets as well as therapeutics that enhance immune-mediated pathogen elimination, disrupt colonisation or biofilm development, and reduce virulence.
  - Discovery of novel therapies to overcome known antimicrobial resistance mechanisms and/or to restore susceptibility to conventional antibiotics.
- New tools/assays:
  - Strategies and/or innovative tools or assays that improve, enhance, and/or facilitate the identification or validation of new effective compounds or therapies.
  - Strategies and/or innovative tools for optimization of drug use, dosage and delivery of new drugs.
  - Exploration of bacterial genes e.g. expression of latent gene clusters

**The following sub-topics are not within the scope of the call:**

- Investigations addressing cross-talk between the host and pathogen, as well as the relationship between microbes, environment and infection.
- Studies on bacteria not in the WHO Global priority list above (see page 1).
- Investigations on the initial steps of the infection process.

- Investigations based on, or involving, clinical trials.
- Re-evaluation of existing anti-microbial compounds in the context of their combination with new, innovative targets, compounds or tools.

## 1.2 Ambition of the call

It is expected that through international collaborations combining complementary and synergistic research strengths, this JPIAMR call will contribute to the urgent need to curb the burden associated with the most prioritised infections. It is also a topic area suitable to reinforce academic - industry collaborations. The participation of industry is encouraged. The results of the funded projects should have an added value to society as a whole, the public health and finances by closing knowledge gaps and discovering new therapies. Although stand-alone projects are fully eligible, links with other European or international research programs and initiatives in the field will be of added value.

## 2. Application

### 2.1 Eligibility

Applicants must adhere to the specific regulations of the national funding organisations. Eligibility rules for the consortia are:

- Minimum of three (3) eligible partners from three (3) different countries participating in the call.
- Maximum of six (6) project partners. However, consortia including partners from Czech Republic, Egypt, Latvia, Poland or Romania may increase the total number of partners to seven (7), in order to increase representation of these countries in JPIAMR projects.
- **Maximum number of partners from each participating country per project** is limited to one partner for **Italy** and to **two partners for other participating countries. For Belgium this is limited to one partner per region/community, which in practice comes down to one partner per participating Belgian funding agency.**
- Participants not eligible for funding (e.g. from non-funding countries or not fundable according to national/regional regulations of the participating funding organisations) may be involved in projects if they secure their own funding. However, **the maximum number of six (6) participants should not be exceeded** (or seven (7) in the case of inclusion of partners from Czech Republic, Egypt, Latvia, Poland or Romania).
- Non-funded partners can participate if they have a secure funding for participation. Consortia should always consist of a majority of project participants eligible for funding according to the criteria above. The budget of a non-funded partner shall not exceed 30% of total transnational project budget requested.
- Project participants not eligible to be funded cannot be consortium coordinators and must accept all JPIAMR rules and guidelines just as funded members.

Number of partners requesting funding (eligible partners)	3	4	5	6	6 (only with at least a partner from Czech Republic, Egypt, Latvia, Poland or Romania)	7 (only with at least a partner from Czech Republic, Egypt, Latvia, Poland or Romania)
Maximum number of additional partners with own funding	2	2	1	0	1	0

## 2.2 Submission of joint transnational proposal

Submissions of proposals will be in two steps. In both cases, one joint proposal document (in English, and following the provided template) shall be prepared by the project participants of a joint transnational proposal, and must be submitted by the coordinator to the submission tool implemented on the JPIAMR website.

The two-step application process (pre-proposal, full proposal) will have the following timetable:

January 11 <sup>th</sup> 2018	<b>Publication of the JPIAMR ERA-NET 2018 Call</b>
March 7 <sup>th</sup> 2018 (17:00 CET)	<b>Submission deadline for pre-proposals</b>
Beginning May 2018	<b>Full proposal invitations send to project coordinators</b>
June 14 <sup>th</sup> 2018 (17:00 CET)	<b>Submission deadline for full proposals</b>
October/November 2018	<b>Final funding decision announced to applicants</b>
End of 2018/Early 2019	<b>Start of funding</b>

## 2.3 Financial modalities and funding prerequisites

Funding is granted for a maximum of three years in accordance with national regulations and applicable legal provisions. **Applicants must comply with their own specific national regulations and scientific remits as detailed in the National and Regional Requirements (see Annex B).**

The financial commitment made by the Parties are listed in the table below. The “virtual common pot model” shall apply for this transnational call. As such, each country will fund its own approved project partners. The proposals will be funded following the ranking list recommended by the Peer Review Panel.

### Anticipated funding provided by each Party

<b>Country</b>	<b>Name of Organisation</b>	<b>Acronym</b>	<b>Contribution (M€)</b>
Belgium	Research Foundation-Flanders	FWO	0.2
Belgium	Fund for Scientific Research-FNRS	F.R.S.-FNRS	0.2
Czech Republic	Ministry of Education, Youth and Sports	MSMT	0.25
Egypt	Academy of Scientific Research and Technology- Egyptian Ministry of Higher Education and Scientific Research	ASRT	0.25
Finland	Academy of Finland	AKA	0.3
France	The French National Research Agency	ANR	1.5
Germany	Federal Ministry of Education and Research	DLR/BMBF	5
Ireland	Health Research Board	HRB	0.37
Israel	Chief Scientist Office, Ministry of Health	MOH-CSO	0.3
Italy	Ministry of Health	MOH	0.5
Latvia	State Education Development Agency	VIAA	0.42
Norway	The Research Council of Norway	RCN	1.5
Poland	National Science Centre	NCN	0.5
Romania	Ministry of Research and Innovation	MCI	0.25
Spain	Ministry of Economy, Industry and Competitiveness – State Research Agency	MINECO-AEI	0.5
Spain	National Institute of Health Carlos III	ISCIII	0.25
Sweden	Swedish Research Council	SRC	1.5
Switzerland	Swiss National Science Foundation	SNF	0.6

### 2.4 Contact persons

The only official communication line of the proposal is between the Joint Call Secretariat (JCS) and the project coordinator. The project coordinator will be the person contacted by the JCS during the application procedure, so he/she must forward this information to other participants. Each funding organisation has national contact persons who can be contacted for information about the specific national requirements (see Annex A).

The JCS is hosted by the French National Research Agency (ANR). The contact details are:

Virginie Mouchel, Martine Batoux

[JPI-AMRCalls@agencerecherche.fr](mailto:JPI-AMRCalls@agencerecherche.fr)

Tel. +33 (0)1 78 09 80 44

Please note that country specific requirements might apply to this call. Compliance with the national/regional regulations specified in the country specific information is mandatory (See Annex B). We strongly advise you to contact your national/regional representative prior to submitting a pre-proposal.

### 3. Evaluation

Pre-proposals and full proposals will be assessed according to specific evaluation criteria (see below), using a common evaluation form. A scoring system from 0 to 5 will be used to evaluate the proposal's performance with respect to the different evaluation criteria.

#### Scoring system:

**0: Failure.** The proposal fails to address the criterion in question, or cannot be judged because of missing or incomplete information.

**1: Poor.** The proposal shows serious weaknesses in relation to the criterion in question.

**2: Fair.** The proposal generally addresses the criterion, but there are significant weaknesses that need corrections.

**3: Good.** The proposal addresses the criterion in question well but certain improvements are necessary.

**4: Very good.** The proposal addresses the criterion very well, but small improvements are possible.

**5: Excellent.** The proposal successfully addresses all aspects of the criterion in question.

#### Evaluation criteria:

##### 1. Excellence

- a. Clarity and pertinence of the objectives
- b. Credibility of the proposed approach and methodology
- c. Soundness of the concept
- d. Innovative potential
- e. Competence and experience of participating research partners in the field(s) of the proposal (previous work in the field, specific technical expertise)

##### 2. Impact

- a. Potential of the expected results for future clinical, public health and/or other socio-economic health relevant applications including patient needs
- b. Added value of transnational collaboration: gathering a critical mass of patients/biological material, sharing of resources (models, databases, diagnosis etc.), harmonisation of data, sharing of specific know-how and/or innovative technologies
- c. Effectiveness of the proposed measures to exploit and disseminate the project results (including management of IPR), to communicate the project, and to manage research data where relevant
- d. Industry and Patient Organisation participation/engagement (when appropriate/applicable)

##### 3. Quality and efficiency of the implementation

- a. Coherence and effectiveness of the work plan, including appropriateness of the allocation of tasks, resources and time
- b. Complementarity of the participants within the consortium
- c. Appropriateness of the management structures and procedures, including risk and innovation management
- d. Concept for sustainability of infrastructures initiated by the project

- e. Budget and cost-effectiveness of the project (rational distribution of resources in relation to project's activities, partner responsibilities and time frame)

Evaluation scores will be awarded for the three main criteria, and not singularly for the different aspects listed below the criteria. The threshold for individual criteria will be three. The maximum score that can be reached from all three criteria together is 15 points.

#### **4. Reporting requirements and other obligations of JPIAMR grantees**

Each partner from selected projects will be funded through national grants from their respective funding agency. National reporting requirements apply according to the national rules of each specific country (See Country-specific information).

Each funded consortium should provide a consortium agreement (CA) signed by all participants. The project participants are encouraged to sign this CA before the start of the project in order to deal with the issues related to the protection of Intellectual Property (such as licensing in, licensing out, patent and exploitation strategy). All points that should be addressed in the CA are detailed in the Annex C.

In addition, grantees have an obligation to submit progress and final scientific reports to the JPIAMR Joint Call Secretariat and supply the JPIAMR with updated information of the consortium and its results for promotion of the call.

All dissemination of results from the funded projects should acknowledge funding from the JPIAMR. Coordinators are expected to participate in and contribute to JPIAMR workshops and other events associated with this call.

**For more information please see [www.jpiamr.eu](http://www.jpiamr.eu).**

#### Annex A: National contact persons for each party providing funding

<b>Country</b>	<b>Funding org.</b>	<b>Contact person(s)</b>	<b>Email</b>
Belgium	FWO	Alain Deleener Toon Monbaliu	<a href="mailto:eranet@fwo.be">eranet@fwo.be</a>
Belgium	F.R.S.-FNRS	Florence Quist Joël Groeneveld	<a href="mailto:florence.quist@frs-fnrs.be">florence.quist@frs-fnrs.be</a> <a href="mailto:Joel.groeneveld@frs-fnrs.be">Joel.groeneveld@frs-fnrs.be</a>
Czech Rep.	MSMT	Daniel Hanspach	<a href="mailto:Daniel.Hanspach@msmt.cz">Daniel.Hanspach@msmt.cz</a>
Egypt	ASRT	Amr Radwan	<a href="mailto:radwan.amro@gmail.com">radwan.amro@gmail.com</a>
Finland	AKA	Sirpa Nuotio	<a href="mailto:sirpa.nuotio@aka.fi">sirpa.nuotio@aka.fi</a>
France	ANR	Virginie Mouchel Martine Batoux	<a href="mailto:JPI-AMRCalls@agencerecherche.fr">JPI-AMRCalls@agencerecherche.fr</a>
Germany	DLR	Barbara Junker Akin Akkoyun	<a href="mailto:Barbara.Junker@dlr.de">Barbara.Junker@dlr.de</a> <a href="mailto:akin.akkoyun@dlr.de">akin.akkoyun@dlr.de</a>
Ireland	HRB	Catriona Creely	<a href="mailto:Ccreely@hrb.ie">Ccreely@hrb.ie</a>
Israel	MOH-CSO	Ayelet Zamir	<a href="mailto:ayelet.zamir@moh.gov.il">ayelet.zamir@moh.gov.il</a>
Italy	MOH	Maria Josè Ruiz Alvarez Giselda Scalera	<a href="mailto:mj.ruizalvarez-esterno@sanita.it">mj.ruizalvarez-esterno@sanita.it</a> <a href="mailto:research.EU.dgric@sanita.it">research.EU.dgric@sanita.it</a>
Latvia	VIAA	Uldis Berkis	<a href="mailto:Uldis.Berkis@viaa.gov.lv">Uldis.Berkis@viaa.gov.lv</a>
Norway	RCN	Sonja Prehn Dyveke Hetland	<a href="mailto:sp@rcn.no">sp@rcn.no</a> <a href="mailto:dhe@rcn.no">dhe@rcn.no</a>
Poland	NCN	Jerzy Fraczek Jolanta Palowska	<a href="mailto:Jerzy.Fraczek@ncn.gov.pl">Jerzy.Fraczek@ncn.gov.pl</a> <a href="mailto:Jolanta.Palowska@ncn.gov.pl">Jolanta.Palowska@ncn.gov.pl</a>
Romania	ANCS	Ioana Ispas	<a href="mailto:ioana.ispas@ancs.ro">ioana.ispas@ancs.ro</a>
Spain	MINECO-AEI	Victoria Sanz Montemayor	<a href="mailto:amr@aei.gob.es">amr@aei.gob.es</a>
Spain	ISCIII	Rafael De Andrés Medina Dori Campo Prieto	<a href="mailto:rdandres@isciii.es">rdandres@isciii.es</a> <a href="mailto:doricampo@isciii.es">doricampo@isciii.es</a>
Sweden	SRC	Kristian Haller Patriq Fagerstedt Laura Plant	<a href="mailto:Kristian.Haller@vr.se">Kristian.Haller@vr.se</a> <a href="mailto:patriq.fagerstedt@vr.se">patriq.fagerstedt@vr.se</a> <a href="mailto:laura.plant@vr.se">laura.plant@vr.se</a>
Switzerland	SNF	Barbara Flückiger Schwarzenbach	<a href="mailto:barbara.flueckiger@snf.ch">barbara.flueckiger@snf.ch</a>



## Annex B: Specific National and Regional Requirements

### Belgium – FWO

<b>Funding of industrial partners</b>	No
<b>Participation of industry required?</b>	No
<b>Maximum funding</b>	200,000 EUR /1 project/ 3 years
<b>Eligible costs</b>	Funding money can be used for staff, consumables and infrastructure. The minimal and maximal amounts of money allowed per cost category, as applicable for the regular FWO-projects, are not applicable for the projects funded by FWO in ERA-NET.  Overhead is not an eligible cost. Notwithstanding, FWO pays the host institutions of a project 6% overhead on top of the funding amount.
<b>Additional documents required</b>	No
<b>Other national restrictions</b>	<a href="#">See national regulations</a>

### Belgium – F.R.S.-FNRS

<b>Funding of industrial partners</b>	No
<b>Participation of industry required?</b>	No
<b>Maximum funding</b>	200.000 EUR/project
<b>Eligible costs</b>	All eligibility rules and criteria can be found in the <a href="#">PINT-MULTI regulations</a> . It is <b>strongly advised</b> to contact the F.R.S.-FNRS prior to submission regarding the eligibility criteria
<b>Additional documents required</b>	Yes
<b>Other national restrictions</b>	See <a href="#">PINT-MULTI regulations</a> .

## Czech Republic - MSMT

<b>Funding of industrial partners</b>	No (participation possible only at own expense)
<b>Participation of industry required?</b>	No
<b>Maximum funding</b>	250,000 EUR altogether (no max. limit per project)
<b>Eligible costs</b>	<p>Eligible costs for a Czech participant involved in a project consortium are defined by <b>§ 2 of the Act No. 130/2002 Coll. on Support of Research, Experimental Development and Innovation from Public Funds</b> and on Amendment to Some Related Acts. The maximum indirect costs set for the present call are <b>25 % (flat rate)</b> of direct costs without the sub-contracting.</p> <p>The <b>aid intensity</b> for activities carried out by a research organisation might be at the level of <b>100 %</b> provided that the research organisation complies entirely with requirements stipulated by the Article 2.1.1 “Public funding of non-economic activities” of the <a href="#">Framework for State Aid for Research and Development and Innovation (2014/C 198/03)</a> and proves it by means of the above-mentioned <b>Statutory Declaration</b>.</p> <p>Should the above-stated criteria not be fulfilled by the Czech participant, funding rates will be adjusted appropriately by the Ministry of Education, Youth and Sports and will reach the level of <b>100 % for fundamental/basic research</b> activities, <b>50 % for applied research</b> activities and <b>25 % for experimental development</b> activities.</p> <p>Each Czech participant in a project consortium is requested to specify the costs related to the envisaged R&amp;D activities in detail by using the <b>Eligible Costs Specification</b> template available on websites of the Ministry of Education, Youth and Sports: <a href="http://www.msmt.cz/vyzkum-a-vyvoj-2/iniciativa-spolecneho-programovani-antimikrobialni">http://www.msmt.cz/vyzkum-a-vyvoj-2/iniciativa-spolecneho-programovani-antimikrobialni</a>.</p>
<b>Additional documents required</b>	<p>All of the requested documentation (i.e. Statutory Declaration and Eligible Costs Specification) shall be sent by each Czech participant in a project consortium to the Ministry of Education, Youth and Sports no later than <b>4<sup>th</sup> July 2017</b> both by electronic correspondence and post.</p> <p>The <b>electronic version</b> of requested documentation shall be sent to the address of electronic correspondence <a href="mailto:daniel.hanspach@msmt.cz">daniel.hanspach@msmt.cz</a>.</p> <p>One <b>signed and stamped hard copy</b> (by the statutory representative of research organisation) of requested documentation shall be submitted as well following the instructions stipulated on websites of the Ministry of Education, Youth and Sports: <a href="http://www.msmt.cz/vyzkum-a-vyvoj-2/iniciativa-spolecneho-programovani-antimikrobialni">http://www.msmt.cz/vyzkum-a-vyvoj-2/iniciativa-spolecneho-programovani-antimikrobialni</a>.</p>

<p><b>Other national restrictions</b></p>	<p>The participants from the Czech Republic in the project consortia must meet the criteria of <b>research and knowledge-dissemination organisation</b> (hereinafter referred to as the “research organisation”) in accordance with the <a href="#">Framework for State Aid for Research and Development and Innovation (2014/C 198/03)</a>. These might be public universities, public research institutes and/or another entities classified as research organisations.</p> <p>It is obligatory that the Czech participants involved in the project consortia prove compliance with the eligibility criteria and fulfilment of the conditions set by <b>§ 18 of the Act No. 130/2002 Coll. on Support of Research, Experimental Development and Innovation from Public Funds</b> and on Amendment to Some Related Acts by means of a <b>Statutory Declaration</b>. The required procedure is described and the Statutory Declaration template is available on the websites of Ministry of Education, Youth and Sports: <a href="http://www.msmt.cz/vyzkum-a-vyvoj-2/spolecne-programovani">http://www.msmt.cz/vyzkum-a-vyvoj-2/spolecne-programovani</a>.</p>
---	---

## Egypt - ASRT

<b>Funding of industrial partners</b>	Yes
<b>Participation of industry required?</b>	SME participation is not mandatory
<b>Maximum funding</b>	€ 50.000 per project
<b>Eligible costs</b>	<ul style="list-style-type: none"> <li>a- Incentives up to 40% of the total eligible costs</li> <li>b- Costs that are necessary for fulfilling the objectives of the project and include, but not restricted to, manufacturing of specimens &amp; prototypes, IP protection and publication, acquiring access to specialized reference source databases or computer software, fees for use of facilities in other national institutions, etc.</li> <li>c- Materials, kits and consumables</li> <li>d- Equipment (shall be fully justified and must not exceed 25% of the total budget per Egyptian partner)</li> <li>e- Travel and subsistence costs. Daily subsistence costs are calculated according to the current governing rules of the Mission Directorate, Ministry of Higher Education, and depending on the visited country. Sometimes are limited by the host institution's internal regulations and in this respect, Egyptian beneficiaries must provide their own local travel policy during the contractual phase (no need to annex the relevant travel policy to the proposal). In general, the most economical means of transport consistent with effective pursuit of the project should be used. Upgrades to business class are to be done at one's own expense.</li> <li>f- Organisational costs of events and projects' meetings.</li> </ul> <p>Indirect costs (overhead costs) can't exceed 5% of the total eligible costs for each Egyptian partner.</p>
<b>Additional documents required</b>	
<b>Other national restrictions</b>	<p><b>Conditions of funding of companies and Private Sector</b></p> <p>This call is also open for private sector including SMEs. Terms of funding companies are based on the local regulations of the Academy of Scientific Research and Technology, in Egypt where beneficiaries are required to either submit a Letter of Guarantee against the fund amount, or follow a post-activity milestone payment schedule.</p>

## Finland – AKA

<b>Funding of industrial partners</b>	No
<b>Participation of industry required?</b>	No
<b>Maximum funding</b>	Max 300 000 € per project (max 2 Finnish participants in the consortium).
<b>Eligible costs</b>	Eligible costs: The same as for applications for Academy of Finland project funding: personnel, consumables, travel, mobility, overheads etc. Full cost model applies; Requested budget from Academy must be no more than 70% of the full costs of a Finnish PI.
<b>Additional documents required</b>	No
<b>Other national restrictions</b>	See national guidelines <a href="http://www.aka.fi/en/funding/how-to-apply/application-guidelines/">http://www.aka.fi/en/funding/how-to-apply/application-guidelines/</a>

## France – ANR

<b>Funding of industrial partners</b>	Yes
<b>Participation of industry required?</b>	No
<b>Maximum funding</b>	Up to 250,000 EUR for a partner. Up to 300,000 EUR for a coordinator Minimum amount requested per partner must exceed : 15,000 EUR.
<b>Eligible costs</b>	Personnel, Consumables, Subcontracts (subcontracting costs of max 50% of requested budget per partner), Small Equipment, Travel. Please note that at ANR « overheads » means « frais généraux de gestion – frais de structure », and 8% of the total eligible costs must be applied if the partner belongs to a public research organisation, or 68% of the total personnel costs and 7% of other costs if you belong to another category (cf <a href="#">règlement financier ANR</a> – section 4.2.1 e).
<b>Additional documents required</b>	No
<b>Other national restrictions</b>	Please find more information in the <a href="#">“Modalités de Participation pour les Participants Français”</a>  ANR will avoid double funding and will not finance projects or part of projects that have been funded through other calls. ANR will cross-check the proposals submitted to ANR through the national and international calls for possible demands of double funding.

## Germany BMBF/DLR

<b>Funding of industrial partners</b>	Yes
<b>Participation of industry required?</b>	No
<b>Maximum funding</b>	No
<b>Eligible costs</b>	See national guidelines
<b>Additional documents required</b>	Scanned signatures of all PIs on full proposal
<b>Other national restrictions</b>	See national guidelines

## Ireland - HRB

<b>Funding of industrial partners</b>	No
<b>Participation of industry required?</b>	No
<b>Maximum funding</b>	370,000 EUR in total (inclusive of overheads and pension contributions) – One project will be funded.
<b>Eligible costs</b>	<p>Salary related costs, small equipment costs, travel, direct running costs, dissemination and knowledge exchange costs, overheads (in accordance with the <a href="#">HRB Policy on Overhead Usage</a>, the HRB will contribute to the indirect costs of the research through an overhead payment of 30% of Total Direct Modifiable Costs (TDMC excludes student fees, equipment and capital building costs) for <b>laboratory or clinically-based research</b> and 25% of Total Direct Modifiable Costs if <b>desk-based research</b>.</p> <p>Applicants from Ireland in consortia invited to submit a full application will be required to provide additional information to the HRB at the time of the full application submission deadline. This will include justification for their requested budget, and clarification on deliverables assigned to the partner from Ireland. A template requesting the information required from applicants from Ireland will be provided by the HRB.</p>
<b>Additional documents required</b>	<p>Applicants from Ireland in consortia invited to submit a full application will be required to provide additional information to the HRB at the time of the full application submission deadline. This will include justification for their requested budget, and clarification on deliverables assigned to the partner from Ireland. A template requesting the information required from applicants from Ireland will be provided by the HRB.</p>
<b>Other national restrictions</b>	<p>Proposals from Irish institutions that include human Embryonic Stem Cell Research will be deemed ineligible</p> <p>Applicants must be affiliated with an <a href="#">HRB host institution</a></p>



## Israel CSO-MOH

<b>Funding of industrial partners</b>	Only on their own funding
<b>Participation of industry required?</b>	No
<b>Maximum funding</b>	Up to 140,000 EUR per project, which are up to 600,000 NIS. Israeli coordinator may request an additional 20,000 EUR, which are up to 100,000 NIS.
<b>Eligible costs</b>	Personnel (students, technicians, applicants excluded); Animals, Materials and consumables; Travel (up to 10%); Institutional overhead 10%. No permanent equipment.
<b>Additional documents required</b>	Prior to submission, researchers will submit to CSO-MOH an abstract approved by their research authority including detailed budget distribution. This abstract describes their work in the consortium. It is not the consortium submitted abstract. No submission of abstract can lead to disqualification of the whole application, as well as the consortium.
<b>Other national restrictions</b>	Research will not be funded simultaneously by CSO-MOH on more than one grant (ERA-NET or national). Researchers can only apply for one grant from any ERA-NET funded by CSO-MOH or submit only one proposal for any single programme. Please see detailed instructions at <a href="http://www.health.gov.il/research-fund">www.health.gov.il/research-fund</a> . Reports will be submitted annually to CSO-MOH.

<b>Funding of industrial partners eligible?</b>	Only Scientific Institutes for Research, Hospitalisation and Healthcare (Istituti di Ricovero e Cura a Carattere Scientifico pubblici e privati, IRCCS) are eligible. No industrial partners are eligible.
<b>Participation of industry required?</b>	No
<b>Maximum funding</b>	Max 250,000 EUR per project
<b>Eligible costs</b>	Only costs generated during the lifetime of the project can be eligible. Personnel (only ad hoc contracts/consultants/fellowship, max 50% of the requested fund); travel costs and subsistence allowances (max 10% of the requested fund); equipment (rent/leasing only, no limit), consumables (no limit), dissemination of results (publications, meetings/workshops etc.- max 1% of the requested fund); data handling and analysis (no limit); overhead (maximum 10% of the requested fund). (All according to the national regulations). Travel expenses and subsistence allowances associated with training activities only linked to the project.
<b>Additional documents required</b>	The simultaneous participation in proposals submitted to different transnational research calls, funded by the Ministero della Salute, is not allowed to Italian Principal Investigators or other research team members. In order to expedite the eligibility check process, the Ministry of Health will grant an eligibility clearance to the applicants prior to the submission of the pre-proposals. To this end, it is mandatory that the applicants fill out and return a pre-eligibility <a href="#">(Italy MOH mandatory pre-eligibility check form 2018)</a> check form through IRCCS Scientific Directorate or Regional Office Health Research using WFR System 10 days before submitting their pre-proposals to the Joint Call Secretariat. It is strongly recommended that the form, completed and duly signed, is returned at least 10 working days before the pre-proposal submission deadline. Applicants will be sent a written notification of their eligibility status.
<b>Other national restrictions</b>	After the JPI-AMR JTC 2018 peer review has been completed and the final (scientific) ranking list has been performed and endorsed by the Call Steering Committee, the Ministry of Health will invite the principal investigators of the projects approved for funding to enter the formal national negotiations (according to national regulations). The funding of this projects are under the Ricerca Corrente IRCCS rules.

<b>Funding of industrial partners eligible?</b>	<p>1. Funding of industrial partners is eligible only if they represent enterprises entered into the Latvian Commercial registry, assumed they are eligible to do the specific research and are in possession of necessary resources in Latvia. The main scientific activity, should be in Latvia. Limitations of EU legislation apply (R651/2014) together with financial reporting and audit requirements.</p> <p>2. The other category of partner eligible for funding by VIAA is Research institutions: Universities, research institutes, other research institutions – they should be listed in the Latvian register of scientific institutions. Any other type of participants is not covered by VIAA. mandate.</p> <p>Participants must comply with Research and knowledge-dissemination organization criteria (R651/2014).</p>
<b>Participation of industry required?</b>	No
<b>Maximum funding</b>	<p>Per partner: 70,000 EUR/year, i.e. maximum grant per partner</p> <p>210,000 EUR for a 3-year project.</p>
<b>Eligible costs</b>	<ul style="list-style-type: none"> <li>○ Personnel costs incl. taxes;</li> <li>○ Consumables;</li> <li>○ Subcontracts (up to 25% of direct costs), needs detailed justification, includes all external services, project core activities cannot be subcontracted;</li> <li>○ Equipment (only depreciation costs);</li> <li>○ Replaceable and fully consumable during project elements of equipment, materials and animals;</li> <li>○ Travels (according to travel plan);</li> <li>○ Indirect costs (up to 25% of direct costs excluding subcontracting).</li> </ul> <p>Costs must be research and innovation costs, there is no support for other activities</p>
<b>Additional documents required</b>	<p>Applicants might be asked to provide additional information in order to assess their eligibility. Applicants are obliged to provide any information specified by Provisions of the Cabinet of ministers No 259, 26.05.2015 upon request.</p>
<b>Other national restrictions</b>	<p>See Provisions of the Cabinet of Ministers:  <a href="http://likumi.lv/ta/id/274671-atbalsta-pieskirsanas-kartiba-dalibai-starptautiskas-sadarbibas-programmas-petniecibas-un-tehnologiju-joma">http://likumi.lv/ta/id/274671-atbalsta-pieskirsanas-kartiba-dalibai-starptautiskas-sadarbibas-programmas-petniecibas-un-tehnologiju-joma</a></p> <p>They should be followed without any exception. All limits and conditions contained in the Provisions in relation to ERA-NET or ERA-NET Cofund are an eligibility criteria for funding.</p>

## Norway RCN

<b>Funding of industrial partners</b>	Yes
<b>Participation of industry required?</b>	No
<b>Maximum funding</b>	700,000 EUR per project for the total 3 year period
<b>Eligible costs</b>	1.5 M EUR for the total 3 year period
<b>Additional documents required</b>	No
<b>Other national restrictions</b>	See national guidelines. Please note that you can only be the Project manager for one project in this call. However, you can be partner on several applications.

## Poland NCN

<b>Funding of industrial partners eligible?</b>	Yes
<b>Participation of industry required?</b>	No
<b>Maximum funding</b>	NCN call budget: 500,000 EUR
<b>Eligible costs</b>	<p>Please see UNISONO:  <a href="http://www.ncn.gov.pl/sites/default/files/pliki/uchwaly-rady/2017/uchwala31_2017-zal1.pdf?ncn">http://www.ncn.gov.pl/sites/default/files/pliki/uchwaly-rady/2017/uchwala31_2017-zal1.pdf?ncn</a> (p. 5-12).</p> <p><b>Overhead costs</b> must not exceed a maximum of <b>40%</b> of the total eligible costs (excl. equipment) and may not be increased during the course of a research project.</p>
<b>Additional documents required</b>	<p>On the full proposal stage Polish applicants must register their applications in the OSF submission system (UNISONO application). This application includes the following budgettable:  <a href="http://ncn.gov.pl/sites/default/files/pliki/UNISONO_budget_table.xlsx">http://ncn.gov.pl/sites/default/files/pliki/UNISONO_budget_table.xlsx</a>.</p>
<b>Other national restrictions</b>	<p><b>Who can apply?</b>  Any researcher, with a <b>doctoral degree</b>, employed at a Polish institution may act as a Principal Investigator.</p> <p><b>Project duration:</b> 24 or 36 months</p> <p>Polish part of the project submitted within the call must involve <b>basic research</b> (original experimental or theoretical research work undertaken primarily to acquire new knowledge of the underlying foundations of phenomena and observable facts).</p> <p>If one international project includes partners from <b>two different Polish Host Institutions</b>, these institutions must apply as a <b>consortium</b>. Each Host Institution comprising the consortium has a separate budget, but the limit on the remuneration applies to the consortium as a whole (UNISONO, p. 9).</p> <p>Applicants are obliged to adhere to the rules included in the following document (UNISONO):  <a href="http://www.ncn.gov.pl/sites/default/files/pliki/uchwaly-rady/2017/uchwala31_2017-zal1.pdf?ncn">http://www.ncn.gov.pl/sites/default/files/pliki/uchwaly-rady/2017/uchwala31_2017-zal1.pdf?ncn</a></p>

## Romania -- MCI

<b>Funding of industrial partners</b>	No
<b>Participation of industry required?</b>	No
<b>Maximum funding</b>	Up to 200,000 EUR/partner Up to 250,000 EUR/coordinator
<b>Eligible costs</b>	See national guidelines <a href="http://uefiscdi.gov.ro/articole/4271/Dezbatere-publica-pachet-informatii-proiecte-ERA-NET-ERA-NET-">http://uefiscdi.gov.ro/articole/4271/Dezbatere-publica-pachet-informatii-proiecte-ERA-NET-ERA-NET-</a>
<b>Additional documents required</b>	No
<b>Other national restrictions</b>	See national guidelines <a href="http://uefiscdi.gov.ro/articole/4271/Dezbatere-publica-pachet-informatii-proiecte-ERA-NET-ERA-NET-Cofund.html">http://uefiscdi.gov.ro/articole/4271/Dezbatere-publica-pachet-informatii-proiecte-ERA-NET-ERA-NET-Cofund.html</a> .

<b>Funding of industrial partners</b>	No
<b>Participation of industry required?</b>	Encouraged
<b>Maximum funding</b>	The maximum amount of funding is 150,000 € per proposal and legal entity (additional 50,000 € if the Spanish group leader is the coordinator of the international consortium). Only one legal entity per project funded by MINECO-AEI will be allowed.
<b>Eligible costs</b>	<p>Please check the eligibility of costs at the APCIN 2018 call or its equivalent <a href="#">Web link to calls</a>.</p> <ul style="list-style-type: none"> <li>• Personnel costs for temporary employment contracts (scholarships are not eligible).</li> <li>• Current costs, small scientific equipment, disposable materials, travelling expenses and other costs that can be justified as necessary to carry out the proposed activities.</li> <li>• <u>Indirect costs (overheads) or clinical trials (proofs of concept, proofs of principle) are not eligible for funding in the APCIN call.</u></li> </ul>
<b>Additional documents required</b>	No
<b>Other national restrictions</b>	<p>Please check the APCIN 2018 call <a href="#">or its equivalent</a>.</p> <p>Final rules on eligibility will be defined in the APCIN 2018 call (or its equivalent), to be published <a href="#">here</a>. In any case, the National regulations in Spanish will prevail over the English version.</p>

## Spain - ISCIII

<b>Funding of industrial partners</b>	No
<b>Participation of industry required?</b>	Encouraged
<b>Maximum funding</b>	Up to 150,000 EUR per research group acting as partner Up to 200,000 EUR per research group acting as coordinator
<b>Eligible costs</b>	See: <a href="http://eu-isciii.es/wp-content/uploads/2018/01/2018_JPI-EC-AMR_Elegibility-ISCIII.pdf">ISCIII national eligibility</a> <a href="http://eu-isciii.es/wp-content/uploads/2018/01/2018_JPI-EC-AMR_Elegibility-ISCIII.pdf">http://eu-isciii.es/wp-content/uploads/2018/01/2018_JPI-EC-AMR_Elegibility-ISCIII.pdf</a>
<b>Additional documents required</b>	Applicants invited for full proposal stage have to send the national application
<b>Other national restrictions</b>	See: <a href="http://www.isciii.es/ISCIII/es/contenidos/fd-investigacion/fd-financiacion/fd-convocatorias-ayudas-accion-estrategica-salud/2018/AES_2018.pdf">Acción Estratégica en Salud, AES 2018</a> <a href="http://www.isciii.es/ISCIII/es/contenidos/fd-investigacion/fd-financiacion/fd-convocatorias-ayudas-accion-estrategica-salud/2018/AES_2018.pdf">http://www.isciii.es/ISCIII/es/contenidos/fd-investigacion/fd-financiacion/fd-convocatorias-ayudas-accion-estrategica-salud/2018/AES_2018.pdf</a>



## Sweden - SRC

<b>Funding of industrial partners</b>	No
<b>Participation of industry required?</b>	No
<b>Maximum funding</b>	Max. 300,000 EUR per project (1 Swedish participant in the consortium: max 300,000 EUR, 2 Swedish participants in the consortium: max 300,000 EUR for the both of them together)
<b>Eligible costs</b>	The same as for applications for SRC project grants
<b>Additional documents required</b>	Swedish project leaders participating in the call for support from the Swedish Research Council shall also submit an application using the Swedish Research Council's application system Prisma: <a href="https://prisma.research.se/Go/Apply/97a015c3-c546-4444-9692-a84f00b75b51">https://prisma.research.se/Go/Apply/97a015c3-c546-4444-9692-a84f00b75b51</a>
<b>Other national restrictions</b>	See national guidelines: <a href="http://www.vr.se/inenglish/researchfunding/applyforgrants/conditionsforapplicationsandgrants.4.5adac704126af4b4be280007743.html">http://www.vr.se/inenglish/researchfunding/applyforgrants/conditionsforapplicationsandgrants.4.5adac704126af4b4be280007743.html</a>

## Switzerland - SNSF

<b>Funding of industrial partners</b>	No
<b>Participation of industry required?</b>	No
<b>Maximum funding</b>	No
<b>Eligible costs</b>	See regular SNSF guidelines
<b>Additional documents required</b>	No
<b>Other national restrictions</b>	Projects must fit with the goals of the National Research Programme “Antimicrobial Resistance” (NRP 72): <a href="http://www.nrp72.ch">www.nrp72.ch</a>

## **Annex C: Guidelines for Consortium Agreement for Project Participants**

Each consortium should provide a Consortium Agreement (CA) signed by all participants before the start of the project to clarify the potential IPR matters (such as licensing in, licensing out, and patent and exploitation strategy). The CA must address (as a minimum), the following points:

- Common start date and duration of the research project
- Organisation and management of the project
- Role and responsibilities of each partner, resources and funding
- Confidentiality and publishing
- Intellectual Property Rights
- Decision making within the consortium
- Handling of internal disputes
- The liabilities of the research partners towards one another (including the handling of default of contract).

Any issues regarding funding are a bilateral matter between each project partner and the relevant funding organisation and should be excluded from the CA. The CA together with any other information required by national/regional regulations must be made available on request to the national funding agencies.